Literature DB >> 29883245

Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab.

Meltem Polat1, Selçuk Yüksel2, Nuriye Ünal Şahin3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29883245      PMCID： PMC6314419          DOI： 10.1080/21645515.2018.1486157

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  3 in total

1.  First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.

Authors:  Selçuk Yüksel; Havva Evrengül; Z Birsin Özçakar; Tülay Becerir; Nagihan Yalçın; Emine Korkmaz; Fatih Ozaltin
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

2.  High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.

Authors:  Lucy A McNamara; Nadav Topaz; Xin Wang; Susan Hariri; LeAnne Fox; Jessica R MacNeil
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-07-14       Impact factor: 17.586

Review 3.  Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.

Authors:  A W Dretler; N G Rouphael; D S Stephens
Journal:  Hum Vaccin Immunother       Date:  2018-05-09       Impact factor: 3.452
  3 in total
  4 in total

1.  Reply letter to "Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab".

Authors:  Alexandra W Dretler; Nadine G Rouphael; David S Stephens
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

2.  Risk Analysis of Eculizumab-Related Meningococcal Disease in Japan Using the Japanese Adverse Drug Event Report Database.

Authors:  Yumi Matsumura
Journal:  Drug Healthc Patient Saf       Date:  2020-11-10

3.  Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.

Authors:  Kelsey Sharkey; Peter T Beernink; Joanne M Langley; Soren Gantt; Caroline Quach; Christina Dold; Qin Liu; Manuel Galvan; Dan M Granoff
Journal:  mSphere       Date:  2019-07-03       Impact factor: 4.389

4.  Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

Authors:  Catherine H Bozio; Cheryl Isenhour; Lucy A McNamara
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.